rejuvant life tabs

Longevity supplements report: ChromaDex profile

Latest articles

A single source for longevity nutrition data

Edamam co-founder talks bringing nutrition into the digital world and seeking funding for expansion in food as medicine. When it comes to food nutrition data,...

The Sheekey Science Show – Senotherapeutics

Senotherapeutics are therapeutics strategies that target cellular senescence. They can work by killing senescent cells (senolytics), inhibiting the proinflammatory secretory phenotype of senescent cells (senomorphics)...

Michael Greve commits €300m for rejuvenation start-ups

The founder of Forever Healthy has committed €300 million to advance rejuvenation biotech start-ups – plus exclusive insights from Michael Greve. Michael Greve, founder of...

Capsida Biotherapeutics emerges from stealth with $140m

Versant Ventures and Westlake Village BioPartners launch next-generation gene therapy company with $50m series A; AbbVie collaboration provides $90m for gene therapies for CNS...

Most read

New NAD+ boosting longevity supplement hits the market

Elevant Prime dietary supplement contains a “high purity” form of NMN that has completed safety and toxicology testing. New York based health and wellness brand...

David Sinclair to co-chair $200 million biotech SPAC

Christian Angermayer's Frontier Acquisition Corp. holds significant longevity interest with David Sinclair and Peter Attia as Co-Chairs of the Board. Frontier Acquisition Corporation, a special...

JUVICELL sets sights on lifespan and healthspan

Ten ingredients, one capsule. JUVICELL is on a mission to deliver an all-in-one longevity supplement. Far from just supplementing their diet to ensure an adequate...
Supplement report

Editor's picks

A single source for longevity nutrition data

Edamam co-founder talks bringing nutrition into the digital world and seeking funding for expansion in food as medicine. When it comes to food nutrition data,...

The Sheekey Science Show – Senotherapeutics

Senotherapeutics are therapeutics strategies that target cellular senescence. They can work by killing senescent cells (senolytics), inhibiting the proinflammatory secretory phenotype of senescent cells (senomorphics)...

Michael Greve commits €300m for rejuvenation start-ups

The founder of Forever Healthy has committed €300 million to advance rejuvenation biotech start-ups – plus exclusive insights from Michael Greve. Michael Greve, founder of...
Rejuvant

We dive into ChromaDex: the company behind the successful nicotinamide riboside supplement Tru Niagen®.

Over the coming weeks, we will be bringing you extracts of 11 company profiles from our Longevity supplements report. Each profile includes an assessment of Pre-Clinical and Clinical Studies, Safety and Risks, Target Market and Success Factors and the target Hallmark(s) of Aging for one of their key products.

We also study each of the companies’ IP, team, UVP, product efficacy, competitive advantage, runway and inflection point, and much more. First-up: ChromaDex.

To view a full size version of ChromaDex’s profile please click here.

Longevity Supplements 1.0 Chromadex Summary
.

All about ChromaDex

ChromaDex Corporation is a global bioscience company dedicated to healthy aging. The ChromaDex team, which includes world-renowned scientists, is pioneering research on nicotinamide adenine dinucleotide (NAD+), levels of which decline with age. ChromaDex is the innovator behind NAD+ precursor nicotinamide riboside (NR), commercialised as the flagship ingredient Niagen®. ChromaDex delivers Niagen® as the sole active ingredient in its consumer product Tru Niagen®. In parallel to ongoing research and innovation surrounding NAD+ precursors, ChromaDex continues to build Tru Niagen® as a global brand through its e-commerce business and via strategic partners.

The early focus of ChromaDex, founded in 1999 by Frank Jaksch, was to discover and license early-stage, IP-backed ingredient technologies. In 2004, Dr Charles Brenner discovered that the nutrient nicotinamide riboside (NR) serves as a precursor to NAD+, an essential molecule whose function is implicated in healthy aging.

In 2012, ChromaDex licensed patents for the nutritional and therapeutic uses of NR and commercialised it as Niagen®. After serving on the company’s Board of Directors for several years, entrepreneur Rob Fried (pictured) joined ChromaDex in 2017 to transform the company and was named CEO in 2018. As part of the business transition, ChromaDex launched Tru Niagen® in the US as its flagship consumer product.

“Through a transition from an ingredients business to a direct-to-consumer bioscience company, ChromaDex has remained true to our commitment to innovation, science and safety,” says Mr Fried. ChromaDex’s flagship product is Tru Niagen®, which features Niagen® (patented nicotinamide riboside/NR) as its sole active ingredient. A precursor to NAD+, Niagen® is a healthy aging nutrient that safely and effectively increases NAD+ levels and is the world’s first and only known FDA-safety notified form of NR.

Tru Niagen

Niagen® has achieved acceptance by the leading regulatory bodies in the world, including those in the United States, Canada, the European Union and Australia. ChromaDex considers these approvals and acceptances by the world’s leading authoritative regulatory bodies as a clear, unequivocal recognition of the quality of the company’s science, the safety of Niagen® as an ingredient and the reproducibility of the production process.

Tru Niagen® is available online, and through partnerships with global retailers and distributors.

With quality being a strong business pillar, ChromaDex takes the safety certification process a step further than many other supplement companies by having a legitimate third party annually assess its manufacturing practices.

ChromaDex decided to partner with NSF International as its GMP auditor. NSF enforces standards across scientific industries to verify consumer safety. They dictate the ideal systems and procedures with sound science at the heart of their mission. A track record of successful NSF audits serves as added credibility for companies who want to guarantee to customers that their product is high quality and safe to use. Additionally, ChromaDex is certified by the International Organization for Standardization (ISO), and continues to seek additional certifications to further bolster the confidence of its consumers.

ChromaDex maintains a state-of-the-art laboratory in Longmont, CO, focusing on R&D, regulatory affairs and quality control.

Access to the report and a FREE executive summary can be found here, and check out our other supplements company profiles here.

Comment on this article

Eleanor Garth
Deputy Editor Now a science and medicine journalist, Eleanor worked as a consultant for university spin-out companies and provided research support at Imperial College London and various London hospitals in a former life.
Rejuvant

Most popular

New NAD+ boosting longevity supplement hits the market

Elevant Prime dietary supplement contains a “high purity” form of NMN that has completed safety and toxicology testing. New York based health and wellness brand...

David Sinclair to co-chair $200 million biotech SPAC

Christian Angermayer's Frontier Acquisition Corp. holds significant longevity interest with David Sinclair and Peter Attia as Co-Chairs of the Board. Frontier Acquisition Corporation, a special...

JUVICELL sets sights on lifespan and healthspan

Ten ingredients, one capsule. JUVICELL is on a mission to deliver an all-in-one longevity supplement. Far from just supplementing their diet to ensure an adequate...

Is nicotinamide riboside a safe and effective way to combat aging?

ChromaDex executive highlights the importance of clinical studies to prove the benefits of NAD+ boosting compound. ChromaDex is the company behind the popular healthy aging...
Supplement report

Related articles

Michael Greve commits €300m for rejuvenation start-ups

The founder of Forever Healthy has committed €300 million to advance rejuvenation biotech start-ups – plus exclusive insights from Michael Greve. Michael Greve, founder of...

Capsida Biotherapeutics emerges from stealth with $140m

Versant Ventures and Westlake Village BioPartners launch next-generation gene therapy company with $50m series A; AbbVie collaboration provides $90m for gene therapies for CNS...

Longevity supplements report: Vitalic

Currently in stealth, Vitalic is on a mission to transition longevity from the early adopters on to a mass market through best-in-class marketing. Over the...

FOXO exclusively licenses epigenetic clocks from UCLA

FOXO Technologies' exclusive licence of epigenetic clocks PhenoAge and GrimAge from UCLA could be an insurance game-changer. FOXO Technologies Inc has announced the licence of...

Longevity investment: small sums behind big ideas

Sonia Arrison talks about her journey to becoming an early stage investor and what longevity means to her. While longevity is now seeing increasing interest...
Supps report ad middle